Abbonarsi

Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation - 05/02/20

Doi : 10.1016/j.ahj.2019.11.010 
Joanne S. Sutter, MD a, , Yuliya Lokhnygina, PhD a, James P. Daubert, MD a, b, Tristram Bahnson, MD a, b, Kevin Jackson, MD a, b, Jason I. Koontz, MD a, b, Albert Y. Sun, MD a, b, Donald D. Hegland, MD a, b, Kevin L. Thomas, MD a, b, Larry Jackson, MD a, b, Robert Lewis, MD, PhD a, b, Christopher Granger, MD a, Jonathan P. Piccini, MD, MHS a, b, Brett D. Atwater, MD a, b
a Duke University Medical Center, Durham, NC 
b Duke Center for Atrial Fibrillation, Durham, NC 

Reprint requests: Joanne Sutter, MD, Duke University Medical Center, Durham, NC 27705.Duke University Medical CenterDurhamNC27705

Abstract

Background

Pulmonary wall isolation (PWI) is increasingly used as an adjunctive lesion set to compliment pulmonary vein isolation (PVI), especially in patients with persistent atrial fibrillation (AF). The objective was to compare outcomes of catheter ablation in patients with persistent AF undergoing PVI with and without adjunctive PWI.

Methods

We performed a retrospective study of 558 patients who underwent de novo and repeat ablation for persistent AF. Subjects were matched using propensity score adjustments. Outcomes were freedom from recurrent atrial arrhythmia and adverse events.

Results

Among 558 patients who underwent ablation for persistent AF, 78 (14%) underwent PVI + PWI, 255 (46%) underwent PVI, and 225 (40%) underwent PVI + linear ablation. Stratified logistic regression analysis with propensity matching revealed higher odds of recurrent arrhythmia with PVI + PWI when compared to PVI (odds ratio [OR] 2.25, 95% CI 1.08-4.69, P = .030) and when compared to PVI + linear (OR 2.31, 95% CI 1.01-5.28, P = .048). Within the PVI + PWI group, 57.7% of subjects were in normal sinus rhythm at 6 months compared to 73.9% and 72.2% in PVI and PVI + linear groups, respectively. Adverse events were rare, with 19 events total identified across all groups.

Conclusions

PVI + PWI does not appear to be as effective as PVI or PVI + linear ablation in reducing the recurrence of arrhythmia within 6 months of the index procedure in patients with persistent AF. A prospective, randomized controlled trial comparing these ablation techniques is needed to clarify the role of extensive substrate modification for treatment of persistent AF.

Condensed Abstract

PWI is increasingly used as an adjunctive lesion set to compliment PVI in patients with persistent AF. We performed a retrospective study of 558 patients who underwent de novo and repeat ablation for persistent AF to compare the outcomes between PVI with and without adjunctive PWI. We found an increased incidence in recurrence of AF and other atrial arrhythmias at 6 months in the PVI + PWI cohort compared to PVI with or without additional linear ablation. A prospective, randomized controlled trial comparing these ablation techniques is needed to clarify the role of extensive substrate modification for treatment of persistent AF.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Conflicts of interest: A. Y. S. reports grants for clinical research and education from Medtronic, Biosense Webster, and Merit Medical and serves on the advisory board for Merit Medical. J. P. P. reports grants for clinical research from Abbott, Boston Scientific, and JNJ and serves as a consultant to Abbott and Medtronic. The remaining authors have no conflicts of interest to disclose.
 Anna Gundlund, MD, PhD, served as guest editor for this article.


© 2019  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 220

P. 89-96 - Febbraio 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
  • Gaetano M. De Ferrari, Susanna R. Stevens, Giuseppe Ambrosio, Sergio Leonardi, Paul W. Armstrong, Jennifer B. Green, Malgorzata Wamil, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study Group
| Articolo seguente Articolo seguente
  • Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
  • Marat Fudim, Jacob P. Kelly, Aaron D. Jones, Omar F. AbouEzzeddine, Andrew P. Ambrosy, Stephen J. Greene, Yogesh N.V. Reddy, Kevin J. Anstrom, Brooke Alhanti, Gregory D. Lewis, Adrian F. Hernandez, G. Michael Felker

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.